Frontier Pharma: Pain - Identifying and Commercializing First-in-Class Innovation - Market Research Report
The active pain pipeline is populated by 796 products across all stages of development, which exhibit a highly diverse range of molecular targets. GBI Research's analyses identified 122 first-in-class programs in active development, constituting 13.6% of the pipeline and acting on 65 first-in-class molecular targets, indicating a high degree of innovation.
View full press release